Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.53 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516850 | 0.88 | DPP4 (0.53) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL160189 | 0.88 | DPP4 (0.53) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15533200 | 0.85 | DPP4 (0.42) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15533388 | 0.81 | DPP4 (0.47) | DPP4 | |
| SCHEMBL15533861 | 0.80 | DPP4 (0.43) | DPP4KCNH2 | |
| SCHEMBL13738693 | 0.78 | DPP4 (0.45) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15091721 | 0.72 | DPP4 (0.34) | DPP4 | |
| SCHEMBL12047738 | 0.71 | DPP4 (0.75) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL12047715 | 0.70 | DPP4 (0.74) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL196603 | 0.70 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2854824-A1 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174769-A1 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-28 | — | — | WO | disclosed |